InvestSMART

Argent Biopharma Limited (ASX: RGT) - Share Price

- Current share price for RGT : $0.036

Argent Biopharma Limited (RGT, formerly MGC Pharmaceuticals Ltd), an ASX-listed company,, is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. The company's proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection.

RGT General Information +

ASX Code RGT
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 3
RGT Share Price $0.036
Day High $0.036
Day Low $0.035
Last Close $0.036
RGT Share Price Movement - ( No change )
Prices as at 16:40, 11 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Argent Biopharma Limited (RGT) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Argent Biopharma Limited (RGT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Argent Biopharma Limited (RGT) price-sensitive announcements

RGT - Quarterly Activities/Appendix 4C Cash Flow Report
Argent BioPharma Limited, listed on the ASX as RGT, has released its Quarterly Activities
Argent Biopharma Limited (RGT)
29 Apr 2026 | 9:04 AM
RGT - Half Yearly Report and Accounts
Argent BioPharma Ltd's consolidated interim financial report for the half-year ended 31 De
Argent Biopharma Limited (RGT)
27 Feb 2026 | 6:15 PM
RGT - Provisional Patent Lodged with USPTO for NanoBodies Platform
Argent Biopharma Limited announced the filing of a U.S. provisional patent for its NanoBod
Argent Biopharma Limited (RGT)
25 Feb 2026 | 9:29 AM
RGT - CannEpil - Largest Commercial Shipment Arrives in Ireland
Argent BioPharma Ltd, an Australia-based biopharmaceutical company, announced the successf
Argent Biopharma Limited (RGT)
23 Feb 2026 | 9:31 AM

Argent Biopharma Limited (RGT) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Argent Biopharma Limited (RGT)
ORDINARY FULLY PAID
Health Care $4 Long Term Aquiol Licensing and Supply Agreement 25 May 2026 9:06AM $0.038 $0.036 fallen by 5.26%
Argent Biopharma Limited (RGT)
ORDINARY FULLY PAID
Health Care $4 Final Director's Interest Notice - GH 6 May 2026 9:02AM $0.037 $0.036 fallen by 2.70%
Argent Biopharma Limited (RGT)
ORDINARY FULLY PAID
Health Care $4 Initial Director's Interest Notice - AC 6 May 2026 9:01AM $0.037 $0.036 fallen by 2.70%
Argent Biopharma Limited (RGT)
ORDINARY FULLY PAID
Health Care $4 Appointment of Executive Director 6 May 2026 9:01AM $0.037 $0.036 fallen by 2.70%
Argent Biopharma Limited (RGT)
ORDINARY FULLY PAID
Health Care $4 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 9:04AM $0.038 $0.036 fallen by 5.26%
Argent Biopharma Limited (RGT)
ORDINARY FULLY PAID
Health Care $4 Completion of CannPal Asset Acquisition and Neuvis Option 13 Apr 2026 8:58AM $0.033 $0.036 risen by 9.09%

RGT Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$15.46 -$27.00 -43.20% 0.00 0.00 0.00% 0.0%
2024A -$17.63 -$47.60 8,552.70% 0.00 0.00 0.00% 0.0%
2023A -$16.50 -$0.60 -1.80% 0.00 0.00 0.00% 0.0%

RGT Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Clarity Pharmaceuticals Ltd (CU6) $787M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $1,673M -0.7857 0.0743 1.2000 56.8973 52.9600 24.0727 0.00% 0.00% 0.00%
Argent Biopharma Limited (RGT) $4M -0.4320 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

RGT Directors

Name Position Start Date
Mr Andrew Chapman Executive Director 6 May 2026
Mr Roby Reuven Zomer Non-Executive Chairman, Non-Executive Director 15 Feb 2016
Mr Daniel Robinson Non-Executive Director 1 Dec 2023

Argent Biopharma Limited (RGT) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
15 Oct 2024 ZOMER, Roby Buy Indirect Shares 4,000,000 $0.410 $1,640,000.000
10 Sep 2024 ZOMER, Roby Buy Indirect Shares 1,258,500 $0.400 $503,400.000
6 May 2022 ZOMER, Roby Buy Indirect Shares 819,672 $0.023 $19,192.000

See all changes in directors' interest & trades for Argent Biopharma Limited (RGT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RGT Management

Name Position
Rowan Harland Company Secretary

RGT Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Argent Biopharma Limited (RGT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
3,913,812 (15.06%) Oak Capital Partners LLC
3,405,016 (7.83%) HSBC Custody Nominees (Australia) Limited

RGT Calendar of Events

Date Event
26 February 2027 Report (Interim)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.